Targeting B cells in the treatment of multiple sclerosis: Recent advances and remaining challenges

Therapeutic Advances in Neurological Disorders

Volumn 6, Issue 3, 2013, Pages 161-173

  Lehmann Horn, Klaus ^a   Kronsbein, Helena C ^a   Weber, Martin S ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

anti CD20; antibody; B cell; cellular subsets; experimental autoimmune encephalomyelitis; immune phenotyping; intrathecal; Multiple sclerosis; therapy

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ANTIBODY PRODUCTION; ANTIBODY SECRETING PLASMA CELL; ANTIGEN PRESENTATION; B LYMPHOCYTE; CYTOKINE RELEASE; DEMYELINATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; LYMPHOCYTE FUNCTION; MULTIPLE SCLEROSIS; NONHUMAN; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 84879288884     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612474333     Document Type: Review

References (79)

1. Antonini G. Cox M. Montefusco E. Ferrari A. Conte E. Morino S. et al. (2007) Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 81: 197–199.
2. Araki M. Aranami T. Matsuoka T. Nakamura M. Miyake S. Yamamura T. (2012) Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab. Mod Rheumatol 11 July (Epub ahead of print).
3. Bar-Or A. Fawaz L. Fan B. Darlington P. Rieger A. Ghorayeb C. et al. (2010) Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 67: 452–461.
4. Baranzini S. Jeong M. Butunoi C. Murray R. Bernard C. Oksenberg J. (1999) B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 163: 5133–5144.
5. Barr T. Shen P. Brown S. Lampropoulou V. Roch T. Lawrie S. et al. (2012) B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 209: 1001–1010.
6. Benedetti L. Franciotta D. Vigo T. Grandis M. Fiorina E. Ghiglione E. et al. (2007) Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. Arch Neurol 64: 1531–1533.
7. Benkhoucha M. Molnarfi N. Santiago-Raber M.L. Weber M.S. Merkler D. Collin M. et al. (2012) IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis. J Neuroinflammation 9: 209.
8. Bradl M. Lassmann H. (2009) Progressive multiple sclerosis. Semin Immunopathol 31: 455–465.
9. Breij E. Brink B. Veerhuis R. van den Berg C. Vloet R. Yan R. et al. (2008) Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 63: 16–25.
10. Broglio L. Lauria G. (2005) Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 32: 378–379.
11. Carson K. Evens A. Richey E. Habermann T. Focosi D. Seymour J. et al. (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834–4840.
12. Clifford D. Ances B. Costello C. Rosen-Schmidt S. Andersson M. Parks D. et al. (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68: 1156–64.
13. Colombo M. Dono M. Gazzola P. Roncella S. Valetto A. Chiorazzi N. et al. (2000) Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 164: 2782–2789.
14. Constant S. Sant'Angelo D. Pasqualini T. Taylor T. Levin D. Flavell R. et al. (1995 a) Peptide and protein antigens require distinct antigen-presenting cell subsets for the priming of CD4+ T cells. J Immunol 154: 4915–4923.
15. Constant S. Schweitzer N. West J. Ranney P. Bottomly K. (1995 b) B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol 155: 3734–3741.
16. Cross A. Stark J. Lauber J. Ramsbottom M. Lyons J. (2006) Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 180: 63–70.
17. Dau P. Petajan J. Johnson K. Panitch H. Bornstein M. (1980) Plasmapheresis in multiple sclerosis: preliminary findings. Neurology 30: 1023–1028.
18. Duddy M. Niino M. Adatia F. Hebert S. Freedman M. Atkins H. et al. (2007) Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 178: 6092–6099.
19. El Fassi D. Nielsen C. Kjeldsen J. Clemmensen O. Hegedus L. (2008) Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease. Gut 57: 714–715.
20. Fillatreau S. Sweenie C. McGeachy M. Gray D. Anderton S. (2002) B cells regulate autoimmunity by provision of IL-10. Nat Immunol 3: 944–950.
21. Fontana A. Fierz W. Wekerle H. (1984) Astrocytes present myelin basic protein to encephalitogenic T-cell lines. Nature 307: 273–276.
22. Genovese M. Kinnman N. de La Bourdonnaye G. Pena Rossi C. Tak P. (2011) Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum 63: 1793–1803.
23. Greter M. Heppner F. Lemos M. Odermatt B. Goebels N. Laufer T. et al. (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11: 328–334.
24. Hardy R. (2006) B-1 B cell development. J Immunol 177: 2749–2754.
25. Harp C. Lovett-Racke A. Racke M. Frohman E. Monson N. (2008) Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol 128: 382–91.
26. Hartung H. Kieseier B. (2010) Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Dis 3: 205–216.
27. Hauser S. Waubant E. Arnold D. Vollmer T. Antel J. Fox R. et al. (2008) B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 358: 676–688.
28. Hawker K. O'Connor P. Freedman M. Calabresi P. Antel J. Simon J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460–471.
29. Hong S. Kim J. Chang J. Kim K. Kim S. Lee H. et al. (2009) A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J 50: 280–283.
30. Iwata Y. Matsushita T. Horikawa M. Dilillo D. Yanaba K. Venturi G. et al. (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B 10 cells. Blood 117: 530–541.
31. Kabat E. Moore D. Landow H. (1942) An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest 21: 571–577.
32. Kappos L. Li D. Calabresi P. O'Connor P. Bar-Or A. Barkhof F. et al. (2011) Ocrelizumab in relapsing–remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779–87.
33. Keegan M. Konig F. McClelland R. Bruck W. Morales Y. Bitsch A. et al. (2005) Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 366: 579–582.
34. Korn T. Mitsdoerffer M. Croxford A. Awasthi A. Dardalhon V. Galileos G. et al. (2008) IL-6 controls Th 17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 105: 18460–18465.
35. Kowarik M.C. Cepok S. Sellner J. Grummel V. Weber M.S. Korn T. et al. (2012). CXCL 13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 9: 93.
36. Krumbholz M. Theil D. Derfuss T. Rosenwald A. Schrader F. Monoranu C. et al. (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201: 195–200.
37. Lalive P. Molnarfi N. Benkhoucha M. Weber M. Santiago-Raber M. (2011) Antibody response in MOG(35-55) induced EAE. J Neuroimmunol 240–241: 28–33.
38. Lanzavecchia A. (1985) Antigen-specific interaction between T and B cells. Nature 314: 537–539.
39. Lassmann H. Bruck W. Lucchinetti C. (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7: 115–121.
40. Lehmann-Horn K. Schleich E. Hertzenberg D. Hapfelmeier A. Kumpfel T. von Bubnoff N. et al. (2011) Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders. J Neuroinflammation 8: 146.
41. Litzenburger T. Fassler R. Bauer J. Lassmann H. Linington C. Wekerle H. et al. (1998) B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. J Exp Med 188: 169–180.
42. Lucchinetti C. Bruck W. Parisi J. Scheithauer B. Rodriguez M. Lassmann H. (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47: 707–717.
43. Lyons J. Ramsbottom M. Cross A. (2002) Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein. Eur J Immunol 32: 1905–1913.
44. Lyons J. San M. Happ M. Cross A. (1999) B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 29: 3432–3439.
45. Mackay F. Schneider P. Rennert P. Browning J. (2003) BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 21: 231–264.
46. Magana S. Keegan B. Weinshenker B. Erickson B. Pittock S. Lennon V. et al. (2011) Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 68: 870–878.
47. Magliozzi R. Howell O. Vora A. Serafini B. Nicholas R. Puopolo M. et al. (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130: 1089–1104.
48. Martin Mdel P. Cravens P. Winger R. Kieseier B. Cepok S. Eagar T. et al. (2009) Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 66: 1016–1020.
49. Mauri C. Blair P. (2010) Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol 6: 636–643.
50. Merkler D. Schmelting B. Czeh B. Fuchs E. Stadelmann C. Bruck W. (2006) Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult Scler 12: 369–374.
51. Moulin V. Andris F. Thielemans K. Maliszewski C. Urbain J. Moser M. (2000) B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J Exp Med 192: 475–482.
52. Muhammad K. Roll P. Seibold T. Kleinert S. Einsele H. Dorner T. et al. (2011) Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 70: 1507–1510.
53. Obermeier B. Mentele R. Malotka J. Kellermann J. Kumpfel T. Wekerle H. et al. (2008) Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 14: 688–693.
54. Owens G. Burgoon M. Anthony J. Kleinschmidt-De Masters B. Gilden D. (2001) The immunoglobulin G heavy chain repertoire in multiple sclerosis plaques is distinct from the heavy chain repertoire in peripheral blood lymphocytes. Clin Immunol 98: 258–263.
55. Owens G. Kraus H. Burgoon M. Smith-Jensen T. Devlin M. Gilden D. (1998) Restricted use of VH 4 germline segments in an acute multiple sclerosis brain. Ann Neurol 43: 236–243.
56. Renaud S. Gregor M. Fuhr P. Lorenz D. Deuschl G. Gratwohl A. et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27: 611–615.
57. Rivera A. Chen C. Ron N. Dougherty J. Ron Y. (2001) Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 13: 1583–1593.
58. Rubenstein J. Combs D. Rosenberg J. Levy A. McDermott M. Damon L. et al. (2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101: 466–468.
59. Rubenstein J. Fridlyand J. Abrey L. Shen A. Karch J. Wang E. et al. (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 25: 1350–1356.
60. Sato T. Ishikawa S. Akadegawa K. Ito T. Yurino H. Kitabatake M. et al. (2004) Aberrant B 1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus. Eur J Immunol 34: 3346–3358.
61. Schluesener H. Sobel R. Linington C. Weiner H. (1987) A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 139: 4016–4021.
62. Schulz H. Pels H. Schmidt-Wolf I. Zeelen U. Germing U. Engert A. (2004) Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 89: 753–754.
63. Seifert C.L. Wegner C. Sprenger T. Weber M.S. Brück W. Hemmer B. et al. (2012). Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response. Multiple Sclerosis 18: 1045–1049.
64. Serafini B. Rosicarelli B. Magliozzi R. Stigliano E. Aloisi F. (2004) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 14: 164–174.
65. Soos J. Morrow J. Ashley T. Szente B. Bikoff E. Zamvil S. (1998) Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol 161: 5959–5966.
66. Steinman L. Zamvil S. (2006) How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60: 12–21.
67. Stuve O. Youssef S. Slavin A. King C. Patarroyo J. Hirschberg D. et al. (2002) The role of the MHC class II transactivator in class ii expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease. J Immunol 169: 6720–6732.
68. Tak P. Thurlings R. Rossier C. Nestorov I. Dimic A. Mircetic V. et al. (2008) Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 58: 61–72.
69. Vamvakas E. Pineda A. Weinshenker B. (1995) Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. J Clin Apher 10: 163–170.
70. van der Veen R. Trotter J. Kapp J. (1992) Immune processing of proteolipid protein by subsets of antigen-presenting spleen cells. J Neuroimmunol 38: 139–146.
71. von Budingen H. Gulati M. Kuenzle S. Fischer K. Rupprecht T. Goebels N. (2010) Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce ‘oligoclonal bands’. J Neuroimmunol 218: 134–139.
72. von Budingen H. Kuo T. Sirota M. van Belle C. Apeltsin L. Glanville J. et al. (2012) B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 122: 4533–4543.
73. Weber M. Hemmer B. (2010) Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis. Results Probl Cell Differ 51: 115–126.
74. Weber M. Hemmer B. Cepok S. (2011) The role of antibodies in multiple sclerosis. Biochim Biophys Acta 1812: 239–245.
75. Weber M. Prod'homme T. Patarroyo J. Molnarfi N. Karnezis T. Lehmann-Horn K. et al. (2010) B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann Neurol 68: 369–383.
76. Weinshenker B. O'Brien P. Petterson T. Noseworthy J. Lucchinetti C. Dodick D. et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878–886.
77. Wolf S. Dittel B. Hardardottir F. Janeway C. Jr (1996) Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 184: 2271–2278.
78. Yoshizaki A. Miyagaki T. DiLillo D. Matsushita T. Horikawa M. Kountikov E. et al. (2012) Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491: 264–268.
79. Zhong X. Gao W. Degauque N. Bai C. Lu Y. Kenny J. et al. (2007) Reciprocal generation of Th1/Th17 and T(reg) cells by B 1 and B 2 B cells. Eur J Immunol 37: 2400–2404.